Literature DB >> 6222965

C3b acceptors on human peripheral blood mononuclear cells; characterization and functional role.

A Erdei, G Füst, J Gyenes, Z Fábry, J Gergely.   

Abstract

C3b acceptors (C3bAs) of human peripheral blood mononuclear cells (PBMC) reacting with the labile binding site of nascent C3b(C3bx) have been investigated by the immune adherence (IA) test. In non-cellular systems some conventional chemical groups (OH-, NH-2) have been reported to be the target of the covalent binding of C3bx. Thus it should be assumed that every cell can fix C3bx via its labile binding site and C3bAs are barely saturable. Contrary to this expectation, however, normal human PBMC were found to be heterogeneous from this point of view, as 57 +/- 4% of B cells and 21 +/- 2% of Null cells possess C3bAs while T cells do not. C3bAs of human PBMC are saturable and trypsin-sensitive structures. The covalent nature of the C3bx-C3bA interaction has also been proved. Studying the effect of acceptor-bound C3b on the function of other cell-surface structures, the inhibition of the Fc gamma receptor function and the abolishment of the enhancement of pokeweed mitogen-stimulated blastogenesis by immune complexes were found.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222965      PMCID: PMC1454288     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  Functionally active C1 on the surface of human peripheral lymphocytes: its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes.

Authors:  G Füst; A Erdei; G Sármay; G A Medgyesi; J Gergely
Journal:  Clin Immunol Immunopathol       Date:  1976-05

2.  Interaction between the third complement protein and cell surface macromolecules.

Authors:  S K Law; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

3.  Studies on the mechanism of the complement-mediated inhibition of the Fc and C3 receptors of B lymphocytes.

Authors:  A Erdei; G Füst; G Sármay; G A Medgyesi; J Gergely
Journal:  Clin Immunol Immunopathol       Date:  1977-11

4.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

5.  The effect of immune complex composition on complement activation and complement dependent complex release.

Authors:  E Rajnavölgyi; G Füst; J Kulics; J Ember; G A Medgyesi; J Gergely
Journal:  Immunochemistry       Date:  1978-12

6.  Complement-dependent histaminase release from human granulocytes.

Authors:  J J Herman; I K Rosner; A E Davis; R S Zeiger; M A Arnaout; H R Colten
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

7.  The binding of activated C3 to polysaccharides and immunoglobulins.

Authors:  P J Capel; O Groeneboer; G Grosveld; K W Pondman
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

8.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

9.  Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

10.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.